Fjarde AP Fonden Fourth Swedish National Pension Fund Increases Stock Holdings in United Therapeutics Corporation $UTHR

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 45.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,530 shares of the biotechnology company’s stock after buying an additional 12,650 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in United Therapeutics were worth $24,033,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Leuthold Group LLC increased its holdings in United Therapeutics by 41.4% during the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after buying an additional 3,126 shares during the last quarter. UBS Group AG raised its position in United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after acquiring an additional 70,445 shares during the period. Perpetual Ltd purchased a new position in United Therapeutics in the fourth quarter valued at about $1,059,000. SG Americas Securities LLC boosted its stake in United Therapeutics by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock valued at $13,136,000 after acquiring an additional 12,663 shares during the last quarter. Finally, Brookstone Capital Management grew its position in shares of United Therapeutics by 25.4% during the 4th quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock valued at $3,227,000 after acquiring an additional 1,342 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds Thymmune’s preclinical thymic cell therapy THY-100 and expands UTHR’s regenerative medicine platform, especially for organ transplantation tolerance and related immune disorders. Article Title
• Positive Sentiment: Analysts continue to view UTHR favorably overall, with the stock carrying a Moderate Buy consensus rating. That suggests the market still sees upside support despite recent volatility and insider sales. Article Title
• Neutral Sentiment: CEO Martine A. Rothblatt and EVP Paul Mahon both sold shares this week, which can create a modest overhang for investor sentiment, though these sales were disclosed and do not necessarily signal a change in the company’s fundamentals. Article Title
• Neutral Sentiment: United Therapeutics recently reported quarterly results that missed analyst expectations on both earnings and revenue, so investors may still be weighing the company’s strong long-term growth strategy against softer near-term execution. Article Title

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 8,750 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $538.15, for a total transaction of $4,708,812.50. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,158,119.40. This represents a 31.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $554.61, for a total value of $5,268,795.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,468,914.93. The trade was a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 632,718 shares of company stock valued at $356,533,651 in the last 90 days. 8.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

UTHR has been the subject of several research analyst reports. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Royal Bank Of Canada decreased their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Finally, Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Price Performance

NASDAQ UTHR opened at $555.91 on Friday. The company’s 50 day moving average is $558.34 and its 200-day moving average is $527.84. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The firm has a market cap of $23.60 billion, a P/E ratio of 20.52, a price-to-earnings-growth ratio of 1.82 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the business posted $6.63 earnings per share. Equities analysts expect that United Therapeutics Corporation will post 26.63 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.